Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. / Széplaki, Gábor; Szegedi, Róbert; Hirschberg, Kristóf; Gombos, Tímea; Varga, Lilian; Karádi, István; Entz, László; Széplaki, Zoltán; Garred, Peter; Prohászka, Zoltán; Füst, George.
I: Atherosclerosis, Bind 204, Nr. 1, 2009, s. 315-20.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes
AU - Széplaki, Gábor
AU - Szegedi, Róbert
AU - Hirschberg, Kristóf
AU - Gombos, Tímea
AU - Varga, Lilian
AU - Karádi, István
AU - Entz, László
AU - Széplaki, Zoltán
AU - Garred, Peter
AU - Prohászka, Zoltán
AU - Füst, George
N1 - Keywords: Aged; Aged, 80 and over; Biological Markers; Brain Ischemia; C-Reactive Protein; Case-Control Studies; Cerebral Infarction; Complement Activation; Complement C1 Inactivator Proteins; Complement C1r; Complement C3a; Complement C4b; Complement C5a; Complement Membrane Attack Complex; Disability Evaluation; Female; Humans; Male; Mannose-Binding Lectin; Middle Aged; Peptide Fragments; Prognosis; Severity of Illness Index; Stroke; Time Factors
PY - 2009
Y1 - 2009
N2 - OBJECTIVE: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. METHODS: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. RESULTS: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. CONCLUSION: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.
AB - OBJECTIVE: According to data from animal models, complement activation plays a major role in the brain injury after acute ischemic stroke. Scarce findings are, however, available on the detection of complement activation products in stroke patients. METHODS: We have measured plasma levels of the five complement activation products (C1rC1sC1inh, C4d, C3a, C5a and SC5b-9) in samples of 26 patients with ischemic stroke upon admission. Twenty-six patients with severe carotid atherosclerosis served as patient controls. RESULTS: Levels of two activation products (SC5b-9 and C4d)) were significantly elevated in the plasma of stroke patients, SC5b-9 levels, exhibited significant positive correlation with the clinical severity of stroke, the severity of neurological deficit, as well as with the level of functional disability. CONCLUSION: These findings suggest that complement activation plays an active role in the development of brain infarct. The measurement of complement activation products might help to determine the clinical prognosis after acute ischemic stroke. Furthermore, there is potential usefulness of complement modulating therapy in ischemic stroke.
U2 - 10.1016/j.atherosclerosis.2008.07.044
DO - 10.1016/j.atherosclerosis.2008.07.044
M3 - Journal article
C2 - 18804761
VL - 204
SP - 315
EP - 320
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
IS - 1
ER -
ID: 19440346